Clinical Laserthermia Systems receives SEK 8.1 million order from ClearPoint Neuro
Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) today announced it has received an order for ClearPoint Prism™ Neuro Laser Therapy System products from ClearPoint Neuro, Inc (Nasdaq:CLPT). The order has a value of approximately SEK 8.1 million.
CLS has a commercial collaboration with ClearPoint Neuro in neurosurgery aimed at developing and commercializing a fully integrated system for MRI image-guided stereotactic laser ablation with very high precision. By offering a solution where both companies' technologies are integrated, the user can identify the target tissue, navigate and position the system's laser applicator, and monitor and control the ablation process in the target tissue with very high precision and accuracy. This order is part of ClearPoint Neuro's limited market release in North America and follows a previous order that CLS received in December 2023 of approximately SEK 2.4 million, bringing the total value of the latest deal to approximately SEK 10.5 million.
"These are important orders that represent another milestone in our collaboration with ClearPoint Neuro. The limited market release that ClearPoint Neuro is now conducting in the North American market has proceeded according to plan and this latest order is a step in the ambition to expand the limited market release with additional clinics in addition to the four that are already included in the program. We are receiving a very positive response and important insights from the clinics we are now working with. Insights from the limited market release will form the basis for further system optimization ahead of the full market launch that is planned to begin in the second half of this year," says Dan J. Mogren, CEO of CLS.
The ClearPoint Prism™ Neuro Laser Therapy System enables integration with the ClearPoint neuro navigation platform and MRI scanners from leading manufacturers. The system is now being rolled out in the United States for use within neurosurgery.
Contact information:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 65 active sites in North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 pharmaceutical/biotech companies, academic centers, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide.
For more information, please visit www.clearpointneuro.com.
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-01-2024 08:30 CET.